-transparent.png){kind=logo}
OBJECTIVE To evaluate the use of raltegravir with unboosted atazanavir in combination with one nucleoside reverse transcriptase inhibitor (NRTI) (lamivudine or emtricitabine) as a potentially well-tolerated once-daily (qd) maintenance regimen. METHODS We compared the pharmacokinetics of raltegravir 400 mg twice daily (bid) with raltegravir 800 mg qd in HIV-infected patients (n=17) on unboosted atazanavir (600 mg qd) in combination with lamivudine or emtricitabine. RESULTS The area under the plasma concentration vs. time curve for a dose interval t (AUC0 -t ) of 800 mg qd divided by 2 was not significantly different from the AUC0 -t of 400 mg bid (P=0.664) but the minimum concentration (C min ) was 72% lower with the qd regimen (P=0.002). The regimen was well tolerated and the viral load remained undetectable in all patients during the 6 weeks of the study follow-up. CONCLUSIONS A qd regimen of raltegravir 800 mg, atazanavir 600 mg and lamivudine or emtricitabine resulted in favourable pharmacokinetic profiles and good short-term safety and efficacy data. Larger phase IIb studies are needed to explore this novel regimen.
A Jansen, and
E P H Colbers, and
A J A M van der Ven, and
C Richter, and
J K Rockstroh, and
J C Wasmuth, and
M van Luin, and
D M Burger
December 2010,
Therapeutic drug monitoring,
A Jansen, and
E P H Colbers, and
A J A M van der Ven, and
C Richter, and
J K Rockstroh, and
J C Wasmuth, and
M van Luin, and
D M Burger
April 2012,
Fundamental & clinical pharmacology,
A Jansen, and
E P H Colbers, and
A J A M van der Ven, and
C Richter, and
J K Rockstroh, and
J C Wasmuth, and
M van Luin, and
D M Burger
January 2009,
TreatmentUpdate,
A Jansen, and
E P H Colbers, and
A J A M van der Ven, and
C Richter, and
J K Rockstroh, and
J C Wasmuth, and
M van Luin, and
D M Burger
September 2015,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
A Jansen, and
E P H Colbers, and
A J A M van der Ven, and
C Richter, and
J K Rockstroh, and
J C Wasmuth, and
M van Luin, and
D M Burger
December 2011,
British journal of clinical pharmacology,
A Jansen, and
E P H Colbers, and
A J A M van der Ven, and
C Richter, and
J K Rockstroh, and
J C Wasmuth, and
M van Luin, and
D M Burger
July 2017,
AIDS research and human retroviruses,
A Jansen, and
E P H Colbers, and
A J A M van der Ven, and
C Richter, and
J K Rockstroh, and
J C Wasmuth, and
M van Luin, and
D M Burger
January 2012,
Antiviral therapy,
A Jansen, and
E P H Colbers, and
A J A M van der Ven, and
C Richter, and
J K Rockstroh, and
J C Wasmuth, and
M van Luin, and
D M Burger
July 2011,
AIDS (London, England),
A Jansen, and
E P H Colbers, and
A J A M van der Ven, and
C Richter, and
J K Rockstroh, and
J C Wasmuth, and
M van Luin, and
D M Burger
January 2014,
Antiviral therapy,
A Jansen, and
E P H Colbers, and
A J A M van der Ven, and
C Richter, and
J K Rockstroh, and
J C Wasmuth, and
M van Luin, and
D M Burger
October 2015,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
